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pression with versus without sleep difficulties was associated with lower utility
scores (b-0.04, p0.001), greater work impairment (rate ratio1.4, p0.001), activ-
ity impairment (rate ratio1.30, p0.001), andmore healthcare provider visits (rate
ratio1.31, p0.001). CONCLUSIONS: Sleep difficulties, when combined with de-
pression, are associated with lower quality of life and greater work productivity
loss and health resource use than either sleep difficulties or depression alone, or
neither. Greater attention to sleep problems in depression may lead to better
outcomes.
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COMPARISON OF DIFFERENT COMORBIDITY MEASURES FOR PREDICTING
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OBJECTIVES: Comorbidity risk adjustment methods are increasingly used to re-
duce potential confounding in epidemiological research.We sought to compare the
performances of four comorbidity measures in predicting physical and mental
health among patients with dementia. METHODS: Nationally representative data
from the 2000-2003 Medical Expenditure Panel Survey (MEPS) were used. The Elix-
hauser and the Charlson/D’Hoore, methods were based on the International Clas-
sification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) codes whereas
the Chronic Disease Score (CDS)-1 and the CDS-2 were based on prescription med-
ications. The performances were compared using the R2 obtained from linear re-
gression models. The outcomes of interest were scores on the Medical Outcomes
Short Form-12 (SF-12) Physical Component Scale (PCS) and Mental Component
Scale (MCS). RESULTS: In linear regression models controlling for age and gender
the CDS-2 performed the best (R2 0.242 for PCS, R2 0.157 forMCS) followed by the
Elixhauser (R20.238 for PCS; R20.107 for MCS), the Charlson/D’Hoore (R20.160
for PCS; R20.038 for MCS)and the CDS-1 (R20.154 for PCS; R20.025 for MCS).
Combining the ICD-9-CM based (Elixhauser) measure with the medication based
(CDS-II) measure improved the R2 for both PCS (R2 0.357) and MCS (R20.250).
CONCLUSIONS:We found that CDS-II comorbidity measurement method outper-
forms Elixhauser, Charlson/D’Hoore and CDS-I methods in predicting physical and
mental health in dementia patients studied. Best performance, howver, was ob-
served in themodel that combined diagnoses based (Elixhauser) measure with the
medication based (CDS-II) measure.
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OBJECTIVES: This study examined the burden of depression on employees using
measures ofwork productivity.METHODS: Individuals (18 years of age) employed
full-time with diagnosed depression completed a Web-based computer-generated
25-minute survey in February 2010 (study population identified by Harris Interac-
tive™). The survey used the Patient Health Questionnaire (PHQ-9) to assess depres-
sive symptoms, and the Health and Work Performance Questionnaire (HPQ) and
Work Productivity and Activity Impairment (WPAI) questionnaire to assess absen-
teeism and presenteeism. Higher scores represent more work missed on the HPQ
(hours monthly) and WPAI (% time weekly) absenteeism scales. Higher scores on
the HPQ presenteeism scale (measure of actual performance to possible perfor-
mance, 0-100 scale), and lower scores on the WPAI presenteeism scale (% impair-
ment past 7 days), represent better performance. Work productivity was assessed
by depression severity using a trend test based on an analysis of covariance with
age, gender and PHQ-9 score as independent variables. RESULTS: A total of 1051
full-time employees were evaluated (58% female, mean age 47 yrs). PHQ-9 scores
indicated 423 (40.25%) employees with no depression symptoms, 319 (30.35%) with
mild, 166 (15.79%)withmoderate, 82 (7.80%)withmoderately severe, and 61 (5.80%)
with severe depression. All levels of depression were associated with decreased
work productivity. Both the HPQ (presenteeism [81.04, 73.54, 68.61, 66.10, 61.48, no
depression, mild, moderate, moderately severe, and severe depression groups, re-
spectively], p0.0001) andWPAI (absenteeism [0.92, 3.04, 4.55, 7.43, 14.00] and pre-
senteeism [10.67, 26.17, 38.81, 44.68, 54.31], p0.0001) showed progressive worsen-
ing of work productivity with increasing severity of depression. Pearson’s
coefficient of correlation for WPAI with PHQ-9 was 0.3158 for absenteeism and
0.6055 for presenteeism (p0.0001). CONCLUSIONS: Depression has a significant
impact on work productivity asmeasured by theWPAI and HPQ. Presenteeism and
absenteeism worsened with increasing depression severity, and decreased overall
productivity was seen at all levels of depression severity.
Mental Health – Health Care Use & Policy Studies
PMH58
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OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is clinically
effective for opioid dependence (OD). Ancillary treatment services, however, may
be needed tomaximize treatment efficacy. The purpose of the present studywas to
investigate the one year effect of a disease management program on treatment
outcomes among a national sample of OD patients.METHODS: Opioid dependent
patients new to B-MAT (N1.426) were randomized to receive either B-MAT plus a
patient support program (intervention group, n  987) or B-MAT alone (standard
care group, n  439). The intervention was a confidential, outbound, telephonic
support program designed to provide new B-MAT patients encouragement and
help them resolve problems inherent to early B-MAT treatment. Once enrolled in
the study, all patients completed the Addiction Severity Index (ASI) and Treatment
Services Review (TSR) at various time points over one year. The ASI is a semi
structured interview designed to measure problem severity in seven functional
areas known to be affected by alcohol and drug dependence. The TSR assess utili-
zation of a variety of health, social, legal, employment, and family support services.
RESULTS: Logistic regression analyses controlling for baseline problem severity
and demographics revealed that intervention group subjectswere significantly less
likely to abuse opioids at month 12 (p  .05; exp ()  1.50), and were significantly
more likely to attend 12 step/self-help groupmeetings for substance abuse (p .05;
exp ()  0.71) compared to the standard care group. CONCLUSIONS: Randomiza-
tion to the diseasemanagement program resulted in a decrease in the reported use
of opioids and an increase in self-help group counseling attendance. Supplement-
ing B-MAT with a structured disease management program seems to be an effec-
tive way to improve patient outcomes. Current results replicate, and extend to
B-MAT, findings from other studies of the effect of telephonic intervention pro-
grams on patient outcomes.
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OBJECTIVES: Opioid dependence (OD) results from the continued abuse of opioids,
which includes prescribed medication for pain (i.e., hyrodcodiene, oxycontin) and
“street” opioids including heroin and methadone. Although patients receive the
same OD diagnosis regardless of their opioid of abuse, prescription and “street”
users represent two distinct patient populations, each with their own unique co-
morbidities and psychosocial profiles. The purpose of this study was to compare
the effectiveness of a new diseasemanagement program (DMP) among the various
types of OD patients. METHODS: A national sample of OD patients new to bu-
prenorphine-medication assisted treatment (B-MAT) were enrolled in the study.
The DMP was a confidential, outbound, telephonic support program designed to
provide new B-MAT patients encouragement and help them resolve problems in-
herent to early B-MAT treatment. All patients completed the Addiction Severity
Index at various time points over the course of the year. Patients were classified
into prescription users (n  303) and street users (heroin or methadone; n  103)
based on their reported opioid of abuse. RESULTS: Street users had significantly
higher baseline legal composite scores (0.13 vs. 0.05; p  0.001), while prescription
users had significantly higher baseline medical (0.31 vs. 0.18; p  0.001) and drug
(0.27 vs. 0.25; p 0.05) composite scores. Within-subjects tests revealed significant
decreases on all three composite scores by month twelve. Additionally, group dif-
ferences on the three composite scores were ameliorated by month twelve (p’s 
.10). CONCLUSIONS: OD patients have a diverse range of medical, social, and sub-
stance abuse histories,making the design of anyDMP for this population especially
complicated. Although patients in this study evidenced two conflicting problem
sets, results showed that the DMP worked equally in ameliorating the challenges
faced by each group, indicating good generalizability of this particular DMP.
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OBJECTIVES:WAVE-bd (WideAmbispectiVE study of the clinicalmanagement and
burden of bipolar disorder [BD]) is ongoing to address limitations of longitudinal BD
studies to-date, few of which investigate caregiver burden. Objectives are to pro-
vide reliable, real-world data, including assessment of burden among caregivers
(usually unpaid relatives or friends), an important consideration in BD patient
management.METHODS:Multinational, multicentre, non-interventional, longitu-
dinal study of patients diagnosed with BD with1 mood event in the preceding 12
months (retrospective data collection from index mood event to enrollment, fol-
lowed by a minimum 9months’ prospective follow-up). Patient selection provided
a representative sample of BD populations in daily practice. Caregiver burden was
assessed using the BurdenAssessment Scale (BAS), where scores range 19–76, with
higher scores indicating greater burden. Assessment was carried out once during
any part of the prospective follow-up for one caregiver only per patient. RESULTS:
To-date, 583/2880 patients (BD-I: 21.8%; BD-II: 16.8%) have attended their baseline
appointment with their primary caregiver (caregiver mean age 50.2 years; 57%
female). The majority of caregivers were patients’ partners or parents (44.1% and
33.5%, respectively), with 10 years of education. The professional status of care-
givers was: employed (47.4%), retired (22.7%), homemaker (16.6%), unemployed
(5.8%) and other (7.4%). BAS scores were collected from 574 caregivers, and total
caregiver burden was 47.6  13.7 (n424) for BD-I and 42.4  12.6 (n150) for BD-II
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